Retrospective Analysis Of 934 Primary Nasopharyngeal Carcinoma (Npc) Patients Treated With Conventional External Beam Radiotherapy Alone
T. Lu,N. Cui,W. Luo,C. Zhao,S. Wu,X. Liu,Y. Chen,F. Xie,M. Chen,W. Hu,X. Cao,Y. Xia
DOI: https://doi.org/10.1016/j.ijrobp.2004.07.451
2004-01-01
Abstract:Purpose/ObjectiveTo report the clinical outcome of 934 patients with primary nasopharyngeal carcinoma, treated with conventional external beam radiation therapy alone.Materials/Methods934 patients were treated in the Sun Yat-Sen University Cancer Center, from Jan. 1, 1999 to Dec. 31, 1999. All the patients had primary nasopharyngeal carcinoma, confirmed by histo-pathology, CT and/or MRI. They were staged using the 1992 Chinese FuZhou staging system for nasopharyngeal carcinoma. There were 35 stage I (3.7%), 215 stage II (23.0%), 488 stage III (52.2%) and 196 stage IV (21.0%) patients. The radiation therapy fields were delineated according to the CT/MRI imaging findings on disease extensions. Two lateral opposed isocentric portals with customized blocking were used for the nasopharynx and upper neck. The anterior lower neck field was separated and matched to the superior fields. Using cone-down technique, the nasopharynx received 70Gy. The spinal cord tolerance was respected with the two lateral opposed on cord portals irradiating to 36-40Gy. Conventional external beam radiation therapy was utilized. The tumor dose delivered to the nasopharynx was 69.7Gy ± 2.4Gy, given in daily fractions of 2Gy for 7–7.5 weeks. The boost dose 10Gy/5fractions was delivered when there was still residual diseases in the base skull or the parapharynx at the end of radiotherapeutic course. The delivered doses to the neck were 60-70Gy (positive lymph nodes) and 50Gy (negative lymph nodes) respectively. The boost dose 10Gy/5 fractions was delivered using electron beam when the residual lymph node of the neck was more than 10 mm at the end of radiotherapeutic course.ResultsThe median follow-up time was 40 months (range 1.4–56.1 months). The 1, 2, 3 and 4-year overall survival rates (OS), metastasis-free survival rates (MFS), disease-free survival rates (DFS) and relapse-free survival rates(RFS) were shown in the table 1. The 4-year overall survival rate for stages I, II, III and IV were 89.3%, 81.8%, 77.1% and 65.0% respectively. At the end of the radiotherapeutic course, the percentages for residual disease were 3.1% in the nasopharynx, 9.5% in the cervical lymph nodes, and 1.9% in both the nasopharynx and the cervical lymph nodes. The loco-regional recurrence rate and the distance metastasis rate were 7.2% and 9.2% respectively. The local recurrence percentages were approximately 6.4% for stages T1-T2 disease and 13.0% for stages T3-T4 disease; 1.0% for N0 patients and 7.6% for N1-N3 patients. The median time for the local regional recurrence and the distance metastases were 19.3 months and 12.8 months after radiotherapy.ConclusionsThere was a 10% improvement in the 2, 3 and 4-year overall survival rates when compared to the results of the past 20 years. The possible reasons for the significant improvement may be (1) the target volumes for radiotherapy were delineated according to CT/MRI imaging, and (2) the change from split-course to continuous radiotherapy and thus shorter overall treatment duration. Both factors have contributed to the improved local control leading to survival benefits. However, the survival rates for the patients with locally-advanced disease are still low. It is recommended that patients with locally-advanced disease should be treated with combined radiotherapy and chemotherapy. Purpose/ObjectiveTo report the clinical outcome of 934 patients with primary nasopharyngeal carcinoma, treated with conventional external beam radiation therapy alone. To report the clinical outcome of 934 patients with primary nasopharyngeal carcinoma, treated with conventional external beam radiation therapy alone. Materials/Methods934 patients were treated in the Sun Yat-Sen University Cancer Center, from Jan. 1, 1999 to Dec. 31, 1999. All the patients had primary nasopharyngeal carcinoma, confirmed by histo-pathology, CT and/or MRI. They were staged using the 1992 Chinese FuZhou staging system for nasopharyngeal carcinoma. There were 35 stage I (3.7%), 215 stage II (23.0%), 488 stage III (52.2%) and 196 stage IV (21.0%) patients. The radiation therapy fields were delineated according to the CT/MRI imaging findings on disease extensions. Two lateral opposed isocentric portals with customized blocking were used for the nasopharynx and upper neck. The anterior lower neck field was separated and matched to the superior fields. Using cone-down technique, the nasopharynx received 70Gy. The spinal cord tolerance was respected with the two lateral opposed on cord portals irradiating to 36-40Gy. Conventional external beam radiation therapy was utilized. The tumor dose delivered to the nasopharynx was 69.7Gy ± 2.4Gy, given in daily fractions of 2Gy for 7–7.5 weeks. The boost dose 10Gy/5fractions was delivered when there was still residual diseases in the base skull or the parapharynx at the end of radiotherapeutic course. The delivered doses to the neck were 60-70Gy (positive lymph nodes) and 50Gy (negative lymph nodes) respectively. The boost dose 10Gy/5 fractions was delivered using electron beam when the residual lymph node of the neck was more than 10 mm at the end of radiotherapeutic course. 934 patients were treated in the Sun Yat-Sen University Cancer Center, from Jan. 1, 1999 to Dec. 31, 1999. All the patients had primary nasopharyngeal carcinoma, confirmed by histo-pathology, CT and/or MRI. They were staged using the 1992 Chinese FuZhou staging system for nasopharyngeal carcinoma. There were 35 stage I (3.7%), 215 stage II (23.0%), 488 stage III (52.2%) and 196 stage IV (21.0%) patients. The radiation therapy fields were delineated according to the CT/MRI imaging findings on disease extensions. Two lateral opposed isocentric portals with customized blocking were used for the nasopharynx and upper neck. The anterior lower neck field was separated and matched to the superior fields. Using cone-down technique, the nasopharynx received 70Gy. The spinal cord tolerance was respected with the two lateral opposed on cord portals irradiating to 36-40Gy. Conventional external beam radiation therapy was utilized. The tumor dose delivered to the nasopharynx was 69.7Gy ± 2.4Gy, given in daily fractions of 2Gy for 7–7.5 weeks. The boost dose 10Gy/5fractions was delivered when there was still residual diseases in the base skull or the parapharynx at the end of radiotherapeutic course. The delivered doses to the neck were 60-70Gy (positive lymph nodes) and 50Gy (negative lymph nodes) respectively. The boost dose 10Gy/5 fractions was delivered using electron beam when the residual lymph node of the neck was more than 10 mm at the end of radiotherapeutic course. ResultsThe median follow-up time was 40 months (range 1.4–56.1 months). The 1, 2, 3 and 4-year overall survival rates (OS), metastasis-free survival rates (MFS), disease-free survival rates (DFS) and relapse-free survival rates(RFS) were shown in the table 1. The 4-year overall survival rate for stages I, II, III and IV were 89.3%, 81.8%, 77.1% and 65.0% respectively. At the end of the radiotherapeutic course, the percentages for residual disease were 3.1% in the nasopharynx, 9.5% in the cervical lymph nodes, and 1.9% in both the nasopharynx and the cervical lymph nodes. The loco-regional recurrence rate and the distance metastasis rate were 7.2% and 9.2% respectively. The local recurrence percentages were approximately 6.4% for stages T1-T2 disease and 13.0% for stages T3-T4 disease; 1.0% for N0 patients and 7.6% for N1-N3 patients. The median time for the local regional recurrence and the distance metastases were 19.3 months and 12.8 months after radiotherapy. The median follow-up time was 40 months (range 1.4–56.1 months). The 1, 2, 3 and 4-year overall survival rates (OS), metastasis-free survival rates (MFS), disease-free survival rates (DFS) and relapse-free survival rates(RFS) were shown in the table 1. The 4-year overall survival rate for stages I, II, III and IV were 89.3%, 81.8%, 77.1% and 65.0% respectively. At the end of the radiotherapeutic course, the percentages for residual disease were 3.1% in the nasopharynx, 9.5% in the cervical lymph nodes, and 1.9% in both the nasopharynx and the cervical lymph nodes. The loco-regional recurrence rate and the distance metastasis rate were 7.2% and 9.2% respectively. The local recurrence percentages were approximately 6.4% for stages T1-T2 disease and 13.0% for stages T3-T4 disease; 1.0% for N0 patients and 7.6% for N1-N3 patients. The median time for the local regional recurrence and the distance metastases were 19.3 months and 12.8 months after radiotherapy. ConclusionsThere was a 10% improvement in the 2, 3 and 4-year overall survival rates when compared to the results of the past 20 years. The possible reasons for the significant improvement may be (1) the target volumes for radiotherapy were delineated according to CT/MRI imaging, and (2) the change from split-course to continuous radiotherapy and thus shorter overall treatment duration. Both factors have contributed to the improved local control leading to survival benefits. However, the survival rates for the patients with locally-advanced disease are still low. It is recommended that patients with locally-advanced disease should be treated with combined radiotherapy and chemotherapy. There was a 10% improvement in the 2, 3 and 4-year overall survival rates when compared to the results of the past 20 years. The possible reasons for the significant improvement may be (1) the target volumes for radiotherapy were delineated according to CT/MRI imaging, and (2) the change from split-course to continuous radiotherapy and thus shorter overall treatment duration. Both factors have contributed to the improved local control leading to survival benefits. However, the survival rates for the patients with locally-advanced disease are still low. It is recommended that patients with locally-advanced disease should be treated with combined radiotherapy and chemotherapy.